Gracell Biotechnologies Co. Ltd.
http://www.gracellbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gracell Biotechnologies Co. Ltd.
AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next
Outstanding Q1 growth in sales and profits have pleased the markets, and investors are now keen to hear more about AstraZeneca’s 2030 masterplan at its investor day next month.
AstraZeneca Looks To Many Modalities In Cancer
Mohit Manrao, head of AstraZeneca’s US oncology business unit, explained the company’s diverse approach in an interview, including investments in ADCs, cell therapy and radiopharmaceuticals.
VBP Pains Swell Prompting New China Strategy, Local Innovation Focus
As the rollout of volume-based procurement to more products brings more pain, drug makers are exploring different China strategies. One indicator, though, is clear - local innovation and distribution can’t be ignored anymore.
Chinese-Language Podcast: AZ收购亘喜,MNC本土重磅交易,2024展望
One week into 2024 and there have already been multiple deals between Chinese innovative drug developers and multinational partners, along with the significant acquisition of GracellBio by AstraZeneca. In this Chinese-language podcast, Brian Yang and Dexter Yan invite a guest speaker to discuss the reasons behind the particularly active China biotech deal-making scene.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice